Related Experiment Videos
'Massive transfusion protocols and the use of tranexamic acid'
Elizabeth A Godbey1, Joseph Schwartz2
1Virginia Commonwealth University Health System, Richmond, Virginia, USA.
Current Opinion in Hematology
|August 21, 2018
Summary
Tranexamic acid (TXA) reduces mortality and transfusion needs in bleeding patients. While its use in massive transfusion protocols is common, ongoing research clarifies its thrombotic risks.
Area of Science:
- Medical Science
- Pharmacology
- Critical Care Medicine
Background:
- Tranexamic acid (TXA) is increasingly used in managing bleeding patients.
- Evidence supports TXA's efficacy in pediatric, trauma, and postpartum hemorrhage.
- Its role in massive transfusion protocols (MTPs) is under examination.
Purpose of the Study:
- To review current literature on tranexamic acid (TXA) use in patients at risk for massive transfusion.
- To evaluate the safety and outcomes of TXA in specific bleeding populations.
Main Methods:
- Systematic review of recent articles.
- Analysis of studies including subgroups of massive transfusion patients.
Main Results:
- TXA generally decreases mortality and transfusion requirements in bleeding populations.
- Studies indicate TXA is a common addition to MTPs.
- Conflicting evidence exists regarding TXA's risk for thrombotic events.
Conclusions:
- TXA demonstrates a mortality benefit in various bleeding scenarios.
- Further research is needed to definitively assess the thrombotic risks of TXA in massive transfusion settings.